"Prognostic Value Of Multigene Signatures Vary In Node‐Negative Breast Cancer" — Marilynn Larkin
For women with node‐negative breast cancer, a combination of clinical findings and molecular information from the ROR, BCI and EPclin multigene signatures has significantly more prognostic value for overall and late‐distant recurrence than the IHC4, RS and CTS signatures, researchers say. Charles Shapiro, MD, director of cancer survivorship and translational breast cancer research at the Tisch Cancer Institute and professor of medicine at the Icahn School of Medicine at Mount Sinai noted, “The two best scores, the ROR and the BCI, were not that different, with nearly overlapping 95 percent confidence intervals.” He added that the tests are useful if you are low risk, with a ten‐year risk of distance recurrence of five percent or less. “You may choose to not take any treatment, especially an aromatase inhibitor that is taken for five years and has potential side effects that may make a big impact on your daily quality of life.”
- Charles Shapiro, MD, Director, Cancer Survivorship, Translational Breast Cancer Research, The Tisch Cancer Institute, Professor, Medicine, Icahn School of Medicine at Mount Sinai
Future Breast Imaging and Biopsy Are Not Eliminated After Mastectomy
Oct 09, 2018 View All Press Releases